AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioPharma, Inc. (AYTU) on June 20, 2025. The filing discloses the entry into a material definitive agreement regarding the company's debt facilities with Eclipse Business Capital LLC.
Key Financial Metrics and Debt Structure
The filing details specific changes to the company's debt obligations under the "Eclipse Amendment" to the Loan and Security Agreement:
- Term Loan: The maturity date for the Eclipse Term Loan has been extended to June 12, 2029. The outstanding principal amount was increased to $13.0 million on the closing date.
- Revolving Credit Facility: The maturity date for the Eclipse Revolving Loan has been extended to June 12, 2029.
- Incremental Advance: A $1.5 million incremental advance was added to the borrowing base. This carries an interest rate of SOFR plus 5.50%.
- Repayment Terms: Repayment of the $1.5 million incremental advance begins on August 1, 2025, with monthly payments of $125,000 until fully repaid.
- Borrowing Base: Concentration limits on certain independent pharmacy distributors were revised to 25%.
The filing does not provide data on revenue, profit, cash flow, margins, or overall liquidity positions outside of the specific debt terms mentioned above.
Material Changes
The primary material change is the restructuring of the company's credit facilities with Eclipse Business Capital LLC. This includes extending maturities by approximately four years and increasing the principal debt load through the $1.5 million incremental advance.
Guidance, Outlook, and Risks
The filing references a press release issued on June 23, 2025, regarding these transactions. No specific financial guidance, forward-looking revenue projections, or management commentary on future operational outlook is included in the text of this 8-K. The filing notes that portions of the full agreement exhibit have been omitted to prevent competitive harm.
Investor Verification Checklist
- Verify the total outstanding debt load of the company post-amendment to assess leverage ratios.
- Review the full text of Exhibit 10.1 (Amendment No. 6) for covenants, default provisions, and interest rate floors not detailed in the summary.
- Confirm the company's current cash position to ensure it can meet the $125,000 monthly repayment obligation starting August 1, 2025.
- Check the June 23, 2025 press release (Exhibit 99.1) for additional context on the strategic rationale for the debt extension.